Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
68
PHG Quote, Financials, Valuation and Earnings
Last price:
$31.99
Seasonality move
:
3.6%
Day range:
$31.62 - $32.11
52-week range:
$21.48 - $33.44
Dividend yield:
3.02%
P/E ratio:
30.02x
P/S ratio:
1.52x
P/B ratio:
2.37x
Volume:
705.7K
Avg. volume:
1.1M
1-year change:
19.52%
Market cap:
$30.5B
Revenue:
$20.1B
EPS (TTM):
$1.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
$5.8B | $0.50 | 6.96% | 124.82% | $35.15 |
|
ARGX
argenx SE
|
$1.3B | $6.19 | 87.13% | 205.62% | $1,031.68 |
|
EDAP
EDAP TMS SA
|
$21.3M | -$0.16 | 14.41% | -9.59% | $6.83 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $2.65 |
|
PRQR
ProQR Therapeutics NV
|
$6.1M | -$0.17 | 17.05% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.6M | -$0.93 | 339.4% | -13.99% | $53.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
$32.08 | $35.15 | $30.5B | 30.02x | $0.97 | 3.02% | 1.52x |
|
ARGX
argenx SE
|
$771.53 | $1,031.68 | $47.7B | 42.59x | $0.00 | 0% | 16.45x |
|
EDAP
EDAP TMS SA
|
$4.43 | $6.83 | $165.5M | -- | $0.00 | 0% | 2.35x |
|
MREO
Mereo BioPharma Group Plc
|
$0.39 | $2.65 | $61.4M | -- | $0.00 | 0% | 120.46x |
|
PRQR
ProQR Therapeutics NV
|
$1.59 | $8.88 | $167.5M | -- | $0.00 | 0% | 9.62x |
|
QURE
uniQure NV
|
$17.12 | $53.52 | $1.1B | -- | $0.00 | 0% | 58.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
42.46% | 0.296 | 36.81% | 0.89x |
|
ARGX
argenx SE
|
-- | 0.022 | -- | 4.92x |
|
EDAP
EDAP TMS SA
|
24.46% | -0.031 | 10.36% | 0.94x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.707 | 0.12% | 8.09x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.348 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 7.217 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
$2.7B | $753.1M | 4.8% | 7.99% | 12.69% | $1.4B |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
EDAP
EDAP TMS SA
|
$7M | -$5.8M | -45.27% | -56.97% | -35.49% | -$5.2M |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Koninklijke Philips NV vs. Competitors
-
Which has Higher Returns PHG or ARGX?
argenx SE has a net margin of 7.71% compared to Koninklijke Philips NV's net margin of 25.88%. Koninklijke Philips NV's return on equity of 7.99% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV44.89% $0.48 $22.4B ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About PHG or ARGX?
Koninklijke Philips NV has a consensus price target of $35.15, signalling upside risk potential of 9.57%. On the other hand argenx SE has an analysts' consensus of $1,031.68 which suggests that it could grow by 33.72%. Given that argenx SE has higher upside potential than Koninklijke Philips NV, analysts believe argenx SE is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV0 3 0 ARGXargenx SE15 1 0 -
Is PHG or ARGX More Risky?
Koninklijke Philips NV has a beta of 0.793, which suggesting that the stock is 20.659% less volatile than S&P 500. In comparison argenx SE has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.596%.
-
Which is a Better Dividend Stock PHG or ARGX?
Koninklijke Philips NV has a quarterly dividend of $0.97 per share corresponding to a yield of 3.02%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays 94.78% of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHG or ARGX?
Koninklijke Philips NV quarterly revenues are $5.9B, which are larger than argenx SE quarterly revenues of $948M. Koninklijke Philips NV's net income of $457.4M is higher than argenx SE's net income of $245.4M. Notably, Koninklijke Philips NV's price-to-earnings ratio is 30.02x while argenx SE's PE ratio is 42.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.52x versus 16.45x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.52x 30.02x $5.9B $457.4M ARGXargenx SE16.45x 42.59x $948M $245.4M
-
Which has Higher Returns PHG or EDAP?
EDAP TMS SA has a net margin of 7.71% compared to Koninklijke Philips NV's net margin of -36.13%. Koninklijke Philips NV's return on equity of 7.99% beat EDAP TMS SA's return on equity of -56.97%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV44.89% $0.48 $22.4B EDAPEDAP TMS SA43.02% -$0.16 $36.3M -
What do Analysts Say About PHG or EDAP?
Koninklijke Philips NV has a consensus price target of $35.15, signalling upside risk potential of 9.57%. On the other hand EDAP TMS SA has an analysts' consensus of $6.83 which suggests that it could grow by 54.43%. Given that EDAP TMS SA has higher upside potential than Koninklijke Philips NV, analysts believe EDAP TMS SA is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV0 3 0 EDAPEDAP TMS SA1 2 0 -
Is PHG or EDAP More Risky?
Koninklijke Philips NV has a beta of 0.793, which suggesting that the stock is 20.659% less volatile than S&P 500. In comparison EDAP TMS SA has a beta of -0.158, suggesting its less volatile than the S&P 500 by 115.787%.
-
Which is a Better Dividend Stock PHG or EDAP?
Koninklijke Philips NV has a quarterly dividend of $0.97 per share corresponding to a yield of 3.02%. EDAP TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays 94.78% of its earnings as a dividend. EDAP TMS SA pays out -- of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHG or EDAP?
Koninklijke Philips NV quarterly revenues are $5.9B, which are larger than EDAP TMS SA quarterly revenues of $16.2M. Koninklijke Philips NV's net income of $457.4M is higher than EDAP TMS SA's net income of -$5.9M. Notably, Koninklijke Philips NV's price-to-earnings ratio is 30.02x while EDAP TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.52x versus 2.35x for EDAP TMS SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.52x 30.02x $5.9B $457.4M EDAPEDAP TMS SA2.35x -- $16.2M -$5.9M
-
Which has Higher Returns PHG or MREO?
Mereo BioPharma Group Plc has a net margin of 7.71% compared to Koninklijke Philips NV's net margin of -2923.31%. Koninklijke Philips NV's return on equity of 7.99% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV44.89% $0.48 $22.4B MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About PHG or MREO?
Koninklijke Philips NV has a consensus price target of $35.15, signalling upside risk potential of 9.57%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $2.65 which suggests that it could grow by 586.36%. Given that Mereo BioPharma Group Plc has higher upside potential than Koninklijke Philips NV, analysts believe Mereo BioPharma Group Plc is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV0 3 0 MREOMereo BioPharma Group Plc4 1 0 -
Is PHG or MREO More Risky?
Koninklijke Philips NV has a beta of 0.793, which suggesting that the stock is 20.659% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.310, suggesting its less volatile than the S&P 500 by 68.983%.
-
Which is a Better Dividend Stock PHG or MREO?
Koninklijke Philips NV has a quarterly dividend of $0.97 per share corresponding to a yield of 3.02%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays 94.78% of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHG or MREO?
Koninklijke Philips NV quarterly revenues are $5.9B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Koninklijke Philips NV's net income of $457.4M is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, Koninklijke Philips NV's price-to-earnings ratio is 30.02x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.52x versus 120.46x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.52x 30.02x $5.9B $457.4M MREOMereo BioPharma Group Plc120.46x -- -- -$7M
-
Which has Higher Returns PHG or PRQR?
ProQR Therapeutics NV has a net margin of 7.71% compared to Koninklijke Philips NV's net margin of -381.88%. Koninklijke Philips NV's return on equity of 7.99% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV44.89% $0.48 $22.4B PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About PHG or PRQR?
Koninklijke Philips NV has a consensus price target of $35.15, signalling upside risk potential of 9.57%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 458.18%. Given that ProQR Therapeutics NV has higher upside potential than Koninklijke Philips NV, analysts believe ProQR Therapeutics NV is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV0 3 0 PRQRProQR Therapeutics NV7 0 0 -
Is PHG or PRQR More Risky?
Koninklijke Philips NV has a beta of 0.793, which suggesting that the stock is 20.659% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.200, suggesting its less volatile than the S&P 500 by 79.991%.
-
Which is a Better Dividend Stock PHG or PRQR?
Koninklijke Philips NV has a quarterly dividend of $0.97 per share corresponding to a yield of 3.02%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays 94.78% of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHG or PRQR?
Koninklijke Philips NV quarterly revenues are $5.9B, which are larger than ProQR Therapeutics NV quarterly revenues of $3.4M. Koninklijke Philips NV's net income of $457.4M is higher than ProQR Therapeutics NV's net income of -$12.9M. Notably, Koninklijke Philips NV's price-to-earnings ratio is 30.02x while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.52x versus 9.62x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.52x 30.02x $5.9B $457.4M PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M
-
Which has Higher Returns PHG or QURE?
uniQure NV has a net margin of 7.71% compared to Koninklijke Philips NV's net margin of -2175.87%. Koninklijke Philips NV's return on equity of 7.99% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV44.89% $0.48 $22.4B QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PHG or QURE?
Koninklijke Philips NV has a consensus price target of $35.15, signalling upside risk potential of 9.57%. On the other hand uniQure NV has an analysts' consensus of $53.52 which suggests that it could grow by 212.7%. Given that uniQure NV has higher upside potential than Koninklijke Philips NV, analysts believe uniQure NV is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV0 3 0 QUREuniQure NV9 4 0 -
Is PHG or QURE More Risky?
Koninklijke Philips NV has a beta of 0.793, which suggesting that the stock is 20.659% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.669%.
-
Which is a Better Dividend Stock PHG or QURE?
Koninklijke Philips NV has a quarterly dividend of $0.97 per share corresponding to a yield of 3.02%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays 94.78% of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PHG or QURE?
Koninklijke Philips NV quarterly revenues are $5.9B, which are larger than uniQure NV quarterly revenues of $3.7M. Koninklijke Philips NV's net income of $457.4M is higher than uniQure NV's net income of -$80.5M. Notably, Koninklijke Philips NV's price-to-earnings ratio is 30.02x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.52x versus 58.48x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.52x 30.02x $5.9B $457.4M QUREuniQure NV58.48x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
